


Interactions Between Key Antiretroviral Drugs

Charts reviewed October 2023. Full information available at www.hiv-druginteractions.org

Page 1 of 1

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.



For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Key to symbols

| | |
|---|---|
| ● | These drugs should not be coadministered |
| ■ | Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity - additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option.

Co-formulations

| | |
|------------|---|
| Atripla® | Efavirenz + Emtricitabine + Tenofovir-DF |
| Biktarvy® | Bictegravir + Emtricitabine + Tenofovir alafenamide |
| Combivir® | Lamivudine + Zidovudine |
| Completa® | Emtricitabine + Rilpivirine + Tenofovir-DF |
| Delstrigo® | Doravirine + Lamivudine + Tenofovir-DF |
| Descovy® | Emtricitabine + Tenofovir alafenamide |
| Dovato® | Lamivudine + Dolutegravir |
| Epivlera® | Emtricitabine + Rilpivirine + Tenofovir-DF |
| Evotaz® | Atazanavir + Cobicistat |
| Genvoya® | Elvitegravir + Cobicistat + Emtricitabine + Tenofovir alafenamide |
| Juluca® | Dolutegravir + Rilpivirine |
| Kivexa® | Abacavir + Lamivudine |
| Odefsey® | Emtricitabine + Rilpivirine + Tenofovir alafenamide |
| Prezcobix® | Darunavir + Cobicistat |
| Rezolsta® | Darunavir + Cobicistat |
| Syntuz® | Darunavir + Cobicistat + Emtricitabine + Tenofovir alafenamide |
| Stribild® | Elvitegravir + Cobicistat + Emtricitabine + Tenofovir-DF |
| Temixys® | Lamivudine +Tenofovir-DF |
| Trumeq® | Abacavir + Lamivudine + Dolutegravir |
| Trizivir® | Abacavir + Lamivudine + Zidovudine |
| Truvada® | Emtricitabine + Tenofovir-DF |

Key to abbreviations

| | |
|---------------|---|
| ATV | Atazanavir (Reyataz®) |
| ATV/cobi | Atazanavir/Cobicistat (Evotaz®) |
| ATV + r | Atazanavir + Ritonavir (Reyataz® + Norvir®) |
| DRV/cobi | Darunavir/Cobicistat (Rezolsta®, Prezcobix®) |
| DRV/c/FTC/TAF | Darunavir, cobicistat, emtricitabine, tenofovir alafenamide (Symtuza®) |
| DRV + r | Darunavir + Ritonavir (Prezista® + Norvir®) |
| LPV | Lopinavir (Kaletra®) |
| RTV | Ritonavir (Norvir®) |
| DOR | Doravirine (Pifletro®) |
| DOR/3TC/TDF | Doravirine/Lamivudine/ Tenofovir-DF (Delstrigo®) |
| DPV (VR) | Dapivirine Vaginal Ring |
| EFV | Efavirenz (Sustiva®/Stocin®) |
| ETV | Etravirine (Intelence®) |
| NVP | Nevirapine (Viramune®) |
| RPV | Rilpivirine (Edurant®) |
| ABC | Abacavir (Ziagen®) |
| FTC | Emtricitabine (Emtriva®) |
| 3TC | Lamivudine (Epivir®) |
| TAF | Tenofovir alafenamide |
| ZDV | Zidovudine (Retrovir®) |
| BIC/FTC/TAF | Bictegravir + Emtricitabine + Tenofovir alafenamide (Biktarvy®) |
| CAB PrEP (LA) | Cabotegravir PrEP (long acting) (Apretude®) |
| CAB/PRV (LA) | Cabotegravir + Rilpivirine (long acting) (Cabenuva®) |
| DTG | Dolutegravir (Tivicay®) |
| EVG/c/FTC/TAF | Elvitegravir + Cobicistat + Emtricitabine + Tenofovir alafenamide (Genvoya®) |
| EVG/c/FTC/TDF | Elvitegravir + Cobicistat + Emtricitabine + Tenofovir disoproxil fumarate (Stribild®) |
| RAL | Raltegravir (Isentress®) |
| Enfuvirtide | Enfuvirtide (Fuzeon®) |
| Fostemsavir | Fostemsavir (Rukobia®) |
| Ibalizumab | Ibalizumab-uyik (Trogarzo®) |
| Lenacapavir | Lenacapavir (Sunlenca®) |
| Maraviroc | Maraviroc (Celsentri®, Selzentry®) |

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.